San Francisco, United States
Unlearn.AI is at the forefront of revolutionizing the clinical development sector with its expertise in AI. Founded in 2017, this US-based startup leverages artificial intelligence to enhance clinical trials, making them smarter and more efficient. Targeted within the rapidly evolving industries of AI, Biotechnology, Life Sciences, and Clean Energy, the company has firmly positioned itself as a vital player in technological innovation.
The breakthrough vision of Unlearn.AI is encapsulated by its slogan: "Transforming clinical development by making every trial smarter with AI." This reflects their commitment to improving clinical trial outcomes, potentially accelerating drug approvals and reducing costs.
The recent $50.00M Series C investment, completed on 01 February 2024, showcases strong market validation and growth potential. This round saw participation from a cadre of renowned investors, including EPIC Ventures, Insight Partners, 8VC, DCVC, Wittington Ventures, Altimeter Capital, Mubadala Capital, Radical Ventures, Necessary Ventures, and DCVC Bio. Their backing highlights confidence in Unlearn.AI's innovative capabilities and future trajectory.
CLINEXEL
MONROE BIOMEDICAL RESEARCH LLC